FY2025 Earnings Forecast for NRXP Issued By HC Wainwright

Key Points

• HC Wainwright has issued FY2025 earnings estimates for NRx Pharmaceuticals, projecting an EPS of ($0.57), while the current consensus estimate stands at ($1.75) per share.
• The company reported an EPS of ($0.98) in its latest quarterly earnings, falling short of analysts' expectations of ($0.31) by a significant margin.
• Investors have shown interest in NRx Pharmaceuticals, with several institutional investors increasing their stakes in the company, indicating potential confidence in future performance.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Free Report) - Analysts at HC Wainwright issued their FY2025 EPS estimates for NRx Pharmaceuticals in a report issued on Monday, September 8th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of ($0.57) for the year. HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for NRx Pharmaceuticals' current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals' FY2026 earnings at $0.42 EPS.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last posted its earnings results on Monday, August 18th. The company reported ($0.98) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.67).

A number of other research analysts have also recently issued reports on NRXP. Wall Street Zen raised shares of NRx Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. D. Boral Capital reissued a "buy" rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a report on Monday. Finally, BTIG Research reissued a "buy" rating on shares of NRx Pharmaceuticals in a report on Monday, August 25th. One research analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $34.50.

NRx Pharmaceuticals Trading Down 5.7%

NASDAQ NRXP opened at $2.97 on Thursday. The company has a fifty day simple moving average of $2.81 and a two-hundred day simple moving average of $2.55. The stock has a market cap of $58.84 million, a P/E ratio of -1.33 and a beta of 1.63. NRx Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $6.01.

Institutional Trading of NRx Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC acquired a new stake in shares of NRx Pharmaceuticals in the fourth quarter valued at about $61,000. Squarepoint Ops LLC acquired a new stake in shares of NRx Pharmaceuticals in the fourth quarter valued at about $56,000. Anson Funds Management LP grew its position in shares of NRx Pharmaceuticals by 535.1% in the first quarter. Anson Funds Management LP now owns 1,179,061 shares of the company's stock valued at $2,417,000 after purchasing an additional 993,401 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of NRx Pharmaceuticals by 27.9% in the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company's stock valued at $562,000 after purchasing an additional 37,598 shares during the period. Institutional investors and hedge funds own 4.27% of the company's stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.